Yayın:
Glofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world data

Sadeleştirilmiş öğe sayfası
dc.contributor.authorGülbaş, Zafer
dc.contributor.authorZafer Gülbaş
dc.contributor.authorAnt Uzay
dc.contributor.authorMuhi̇t Özcan
dc.contributor.authorFahir Özkalemkaş
dc.contributor.authorMehmet Sinan Dal
dc.contributor.authorHakan Kalyon
dc.contributor.authorOlga Meltem Akay
dc.contributor.authorBurak Devecı
dc.contributor.authorHüseyin Saffet Beköz
dc.contributor.authorÖmür Gökmen Sevindik
dc.contributor.authorTayfur Toptaş
dc.contributor.authorAsu Fergün Yılmaz
dc.contributor.authorDerya Koyun
dc.contributor.authorNihan Alkış
dc.contributor.authorİnci Alacacıoğlu
dc.contributor.authorMehmet Sönmez
dc.contributor.authorİrfan Yavaşoğlu
dc.contributor.authorAnıl Tombak
dc.contributor.authorÖzgür Mehtap
dc.contributor.authorFatih Kurnaz
dc.contributor.authorOrhan Kemal Yuce
dc.contributor.authorVolkan Karakuş
dc.contributor.authorMehmet Turgut
dc.contributor.authorDerya Deniz Kürekçi
dc.contributor.authorMesut Ayer
dc.contributor.authorMuzaffer Keklık
dc.contributor.authorDeram Büyüktaş
dc.contributor.authorMurat Özbalak
dc.contributor.authorBurhan Ferhanoğlu
dc.contributor.orcid0000-0002-2596-4493
dc.contributor.orcid0000-0002-4709-0627
dc.contributor.orcid0000-0003-1381-4188
dc.contributor.orcid0000-0002-1326-1918
dc.contributor.orcid0000-0001-9710-134X
dc.contributor.orcid0000-0002-5994-2735
dc.contributor.orcid0000-0002-6759-1939
dc.contributor.orcid0000-0001-5820-1903
dc.contributor.orcid0000-0003-1237-8281
dc.contributor.orcid0000-0001-9636-4113
dc.contributor.orcid0000-0002-2690-8581
dc.contributor.orcid0000-0001-5118-6894
dc.contributor.orcid0000-0003-3970-2010
dc.contributor.orcid0000-0002-2176-4371
dc.contributor.orcid0000-0003-1703-2175
dc.contributor.orcid0000-0002-7195-1845
dc.contributor.orcid0000-0002-5603-1178
dc.contributor.orcid0000-0001-9178-2850
dc.contributor.orcid0000-0002-1036-0232
dc.contributor.orcid0000-0003-1977-0104
dc.contributor.orcid0000-0002-6426-5249
dc.contributor.orcid0000-0002-3040-4052
dc.contributor.orcid0000-0002-4257-549X
dc.date.accessioned2025-11-13T09:44:18Z
dc.date.issued2023-05-22
dc.identifier.doihttps://doi.org/10.1002/hon.3174
dc.identifier.endpage673
dc.identifier.issn0278-0232
dc.identifier.issue4
dc.identifier.openalexW4377220608
dc.identifier.startpage663
dc.identifier.urihttps://hdl.handle.net/11421/2043
dc.identifier.urihttps://doi.org/10.1002/hon.3174
dc.identifier.volume41
dc.language.isoen
dc.relation.ispartofHematological Oncology
dc.rightsopenAccess
dc.subjectMedicine
dc.subjectRefractory (planetary science)
dc.subjectInternal medicine
dc.subjectLymphoma
dc.subjectToxicity
dc.subjectCytokine release syndrome
dc.subjectGastroenterology
dc.subjectDiffuse large B-cell lymphoma
dc.subjectProgressive disease
dc.subjectSurgery
dc.subjectNeutropenia
dc.subjectChemotherapy
dc.subjectCancer
dc.subjectImmunotherapy
dc.subjectChimeric antigen receptor
dc.subject.sdg3
dc.titleGlofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world data
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5058571002

Dosyalar

Koleksiyonlar

Publications